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Tumor development depends on a combination of both genetic and epigenetic changes. In order to 
study human cancer biology, genetically engineered mouse models (GEMMs) of cancer are derived 
from either overexpressing oncogenes or silencing tumor suppressors. Few studies have examined 
epigenetic changes in these mouse models. Importantly, GEMMs are used to study the preclinical 
efficacy of drugs. "It is an all but too common story to hear of a compound that showed great 
promise when tested in a mouse model of cancer only to fail when tested in patients," according to 
Dr. Scott Diede in the Clinical Research Division. A new study published in Epigenetics from Dr. 
Diede in the laboratory of Dr. Stephen Tapscott (Human Biology Division) suggests one possible 
reason for this low success rate: mouse models of cancer are fundamentally different with respect to 
DNA methylation compared to human tumor samples. 
One common epigenetic change found in tumors is the addition of methyl groups on cytosine bases 
of DNA located in gene promoters. DNA hypermethylation at these locations turns off the expression 
of genes. In a previous study, Dr. Diede and colleagues found extensive DNA methylation changes 
in human medulloblastoma patient samples that altered expression of genes in critical 
developmental pathways (Diede et al., 2009). To determine if these epigenetic changes were also 
found in three different GEMMs of medulloblastoma, Dr. Diede and colleagues examined DNA 
methylation patterns across the genome for both human and mouse brain tumors compared to 
normal brain tissue. In human tumors, 121 loci had strong promoter DNA methylation (greater than 
60% more methylated than normal cerebellum), while the mouse models exhibited this level of 
hypermethylation in only 0 to 16 loci. When the researchers lowered the stringency of methylation to 
greater than 33% methylated, 315 additional hypermethylated promoters were found for the human 
tumors compared to only 7 to 70 for the three medulloblastoma GEMMs. 
The researchers then asked whether this decreased DNA methylation pattern was found in other 
mouse models of cancer. Compared to human tumors or cancer cell lines, GEMMs of Burkitt 
lymphoma and breast cancer also displayed less promoter DNA hypermethylation. Diede et al. then 
asked if mouse cells are capable of acquiring extensive promoter DNA hypermethylation by  
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examining mouse fibroblasts that spontaneously immortalize under extensive culture. The 
immortalized mouse cells indeed acquired DNA hypermethylation, a phenomenon that is also 
observed in human fibroblasts, suggesting that DNA hypermethylation may contribute to bypassing 
cell senescence in initiating tumor development. However, the researchers hypothesize that this 
event is not required for tumorigenesis in the GEMMs of cancer, at least not the five GEMMs driven 
by overexpressing oncogenes examined in this study. 
"Our results suggest caution when using GEMMs of cancer as preclinical platforms for therapy 
development, especially for those drugs that alter epigenetic modifications such as DNA 
methylation," according to Dr. Diede. "We hope to be able to use this new information to better 
understand human cancer and develop more faithful mouse models to help identify therapies to 
increase cure rates for patients with cancer." 
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Image provided by Dr. Scott Diede 
DNA methylation patterns differ between genetically engineered mouse 
models of cancer and primary human cancers, including 
medulloblastomas. breast cancer and Burkitt lymphoma. 
 
